---
title: "Germline genomic score P-CARE adds risk information beyond PSA for short- and long-term prostate c"
id: "medrxiv-22-additional-value-of-germline-genomic-scores-beyond-prostate-specific-antigen"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-22-additional-value-of-germline-genomic-scores-beyond-prostate-specific-antigen"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1?rss=1"
published_at: "2026-11-19T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Germline genomic score P-CARE adds risk information beyond PSA for short- and long-term prostate c
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-22-additional-value-of-germline-genomic-scores-beyond-prostate-specific-antigen
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1?rss=1)
- **Published At:** 2026-11-19T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators evaluated whether germline genomic risk improves prostate cancer detection when combined with measured **prostate-specific antigen** (PSA). The study used a multicomponent score called **P-CARE** that integrates a 601-variant polygenic hazard score, family history, and genetic ancestry. - The primary cohorts were the VA Million Veteran Program (MVP) for discovery/assessment and the Prostate Cancer Prevention Trial (PCPT) for external validation. - In MVP (N reported in the source), high versus low **P-CARE** risk was associated with increased hazards of treatment and metastasis; the reported hazard ratio for both outcomes was 3.32. - Among men with baseline PSA measured at ages 40–49 and PSA 1–3 ng/mL, 15-year probabilities of treatment or metastasis rose across P-CARE strata: 2.6% (low), 4.5% (intermediate), and 10.2% (high). - High **P-CARE** risk predicted clinically significant prostate cancer on biopsy, with an odds ratio of 2.96. - The alternative polygenic score labeled PRSPSA showed an inverse association with outcomes in the reported analyses. - The study team observed consistent patterns in the external PCPT validation cohort. - Authors propose that germline genomic risk complements measured PSA and supports prospective evaluation of genetically informed screening strategies, but the manuscript is a preprint and has not been peer reviewed. - The UCSD IRB waived ethics oversight for this work, and data supporting MVP analyses are available at dbGAP accession phs001672.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=7A0Lj4.HagQPMANSzRTVnwtGiEy_psyzSSYLWKbm1to-1795159023.644752-1.2.1.1-Wz8WUlbZS6OhvcWYApBKTC_di9303qY1._bXbkBgpzC_TE5obCHlFimrnF2wOWpv) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Additional value of germline genomic scores beyond prostate-specific antigen alone for long-term and near-term prostate cancer risk Roshan Karunamuni, Joshua Stark, George Jiajie Xu, Charles Brunette, Isla Garraway, Richard Hauger, Linda Kachuri, Adam Kibel, Michael Liss, Julie Lynch, Brenton Rose, Craig Teerlink, Jason Vassy, John Witte, VA Million Veteran Program, Tyler Seibert doi: https://doi.org/10.64898/2026.11.17.26368323 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Roshan Karunamuni 1 VA San Diego Healthcare System; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Roshan%2BKarunamuni%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Karunamuni%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARoshan%2BKarunamuni%2B) Joshua Stark 2 University of California San Diego; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Joshua%2BStark%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Stark%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJoshua%2BStark%2B) George Jiajie Xu 2 University of California San Diego; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=George%2BJiajie%2BXu%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Xu%20GJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGeorge%2BJiajie%2BXu%2B) Charles Brunette 3 VA Boston Healthcare System; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Charles%2BBrunette%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Brunette%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACharles%2BBrunette%2B) Isla Garraway 4 David Geffen School of Medicine at UCLA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Isla%2BGarraway%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Garraway%20I&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AIsla%2BGarraway%2B) Richard Hauger 1 VA San Diego Healthcare System; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Richard%2BHauger%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hauger%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARichard%2BHauger%2B) Linda Kachuri 5 Stanford University School of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Linda%2BKachuri%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kachuri%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALinda%2BKachuri%2B) Adam Kibel 6 Brigham and Women's Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Adam%2BKibel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kibel%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAdam%2BKibel%2B) Michael Liss 2 University of California San Diego; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Michael%2BLiss%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Liss%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMichael%2BLiss%2B) Julie Lynch 7 VA Salt Lake City Health Care System * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Julie%2BLynch%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lynch%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJulie%2BLynch%2B) Brenton Rose 1 VA San Diego Healthcare System; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Brenton%2BRose%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Rose%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABrenton%2BRose%2B) Craig Teerlink 7 VA Salt Lake City Health Care System * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Craig%2BTeerlink%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Teerlink%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACraig%2BTeerlink%2B) Jason Vassy 3 VA Boston Healthcare System; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jason%2BVassy%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Vassy%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJason%2BVassy%2B) John Witte 5 Stanford University School of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=John%2BWitte%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Witte%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJohn%2BWitte%2B) Tyler Seibert 1 VA San Diego Healthcare System; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tyler%2BSeibert%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Seibert%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATyler%2BSeibert%2B) * For correspondence: tseibert@health.ucsd.edu * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1349298/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1349298/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1349298/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1349298/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1349298/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1349298/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract We evaluated whether germline genomic risk complements prostate-specific antigen (PSA) for prostate cancer early detection. P-CARE integrates a 601-variant polygenic hazard score, family history, and genetic ancestry. Long-term outcomes and clinically significant prostate cancer (csPCa) detection on biopsy were assessed in the Million Veteran Program (MVP), with external validation in the Prostate Cancer Prevention Trial (PCPT). Among 428,512 MVP participants, high versus low P-CARE risk was associated with increased hazards of treatment (HR 3.32) and metastasis (HR 3.32). Among men whose baseline PSA was measured at ages 40-49 with PSA 1-3 ng/mL, 15-year treatment/metastasis probabilities were 2.6%, 4.5%, and 10.2% across increasing P-CARE risk groups. High P-CARE risk also predicted csPCa on biopsy (OR 2.96), while PRSPSA was inversely associated with outcomes. Findings were consistent in PCPT. Germline genomic risk complements measured PSA, supporting prospective evaluation of genetically informed screening strategies. ### Competing Interest Statement Adam S. Kibel reports funding for work unrelated to this manuscript from Janssen, Pfizer, Profound, Bristol Myers Squibb, and Merck. Craig C. Teerlink and Julie A. Lynch report grants from Alnylam Pharmaceuticals, Astellas Pharma, AstraZeneca Pharmaceuticals, Biodesix, Celgene, Cerner Enviza, GSK, IQVIA, Janssen Pharmaceuticals, Novartis International, and Parexel International through the University of Utah or Western Institute for Veteran Research, outside the submitted work. Michael A. Liss is the founder and president of Oncobiomix and has reported research funding from MicrogenDx. Tyler M. Seibert reports honoraria or consulting fees from Varian Medical Systems, WebMD, MJH Life Sciences, MD Education USA, GE Healthcare, Blue Earth Diagnostics, Janssen, CorTechs Labs, and MyOme. He has stock options in CorTechs Labs, MyOme, and Open Medicine for serving on their scientific advisory boards. He receives research funding and/or in-kind research support from GE Healthcare, Blue Earth Diagnostics, Quibim, AIRA Matrix, Veracyte, and Lantheus, all through the University of California San Diego. These companies might potentially benefit from the research results. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies. The remaining authors declare no competing interests. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: UCSD IRB waived ethics I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Full summary statistics relating to the Million Veteran Program (MVP) studies are available at dbGAP accession phs001672. ## Funder Information Declared United States Department of Veterans Affairs, I01CX002635-01 Prostate Cancer Foundation, 23CHAL12, 24CHAL03 United States Department of Defense, DOD/CDMRP PC220521 NIH, R01CA241410 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.18.26368388v1 "Fine-tuned encoders, generative large language models and typed decisions for classifying findings in chest CT reports: paired English-Japanese internal testing and external testing on naturally written Japanese reports")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.16.26368239v1 "Assessing the Perception of Usefulness and Use of Syndromic Surveillance of Surgical Site Infections for Improvement of Infection Prevention and Control in Health Facilities of Tanzania: A Qualitative Design’ for Publication") Posted November 19, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/19/2026.11.17.26368323.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.11.17.26368323v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/19/2026.11.17.26368323.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Additional value of germline genomic scores beyond prostate-specific antigen alone for long-term and near-term prostate cancer risk Roshan Karunamuni, Joshua Stark, George Jiajie Xu, Charles Brunette, Isla Garraway, Richard Hauger, Linda Kachuri, Adam Kibel, Michael Liss, Julie Lynch, Brenton Rose, Craig Teerlink, Jason Vassy, John Witte, VA Million Veteran Program, Tyler Seibert medRxiv 2026.11.17.26368323; doi: https://doi.org/10.64898/2026.11.17.26368323 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.17.26368323v1%26text%3DAdditional%2520value%2520of%2520germline%2520genomic%2520scores%2520beyond%2520prostate-specific%2520antigen%2520alone%2520for%2520long-term%2520and%2520near-term%2520prostate%2520cancer%2520risk "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.17.26368323v1%26t%3DAdditional%2520value%2520of%2520germline%2520genomic%2520scores%2520beyond%2520prostate-specific%2520antigen%2520alone%2520for%2520long-term%2520and%2520near-term%2520prostate%2520cancer%2520risk "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.17.26368323v1%26title%3DAdditional%2520value%2520of%2520germline%2520genomic%2520scores%2520beyond%2520prostate-specific%2520antigen%2520alone%2520for%2520long-term%2520and%2520near-term%2520prostate%2520cancer%2520risk%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.17.26368323v1%26title%3DAdditional%2520value%2520of%2520germline%2520genomic%2520scores%2520beyond%2520prostate-specific%2520antigen%2520alone%2520for%2520long-term%2520and%2520near-term%2520prostate%2520cancer%2520risk "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.17.26368323) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.17.26368323v1&count=horizontal&via=&text=Additional%20value%20of%20germline%20genomic%20scores%20beyond%20prostate-specific%20antigen%20alone%20for%20long-term%20and%20near-term%20prostate%20cancer%20risk&counturl=www.medrxiv.org/content/10.64898/2026.11.17.26368323v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/a
## Related Clinical Research

- [COMMD1 in Cancer: Dual Roles, Mechanisms, and Translational Targets](https://medichelpline.com/clinical-feed/pubmed-43059391.md) (DOI: 10.3892/or.2026.9224)
- [CD55 Is Induced by PGE2–EP4–Gi–p38 MAPK Signaling in Colorectal Cancer Cells](https://medichelpline.com/clinical-feed/pubmed-42551717.md) (DOI: 10.1016/j.gene.2026.150339)
- [Gland MRI Radiomics Predicts Time to Pathologic Progression on Prostate Cancer Active Surveillance](https://medichelpline.com/clinical-feed/medrxiv-6-automated-gland-mri-radiomics-for-predicting-time-to-pathologic-progression.md)
- [ESMO Congress 2026: Updates on ADCs, bispecifics and RIPTACs](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-from-the-esmo-congress-2026.md)
- [Reassessing Breast Cancer Treatment: The Benefits of De-Escalation](https://medichelpline.com/clinical-feed/plos-medicine-0-breast-cancer-treatment-when-less-is-more.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.